Literature DB >> 25211089

A brief review on human mtDNA mutations and NRTI-associated mtDNA toxicity and mutations.

Koushik Chattopadhyay1, Colleen Aldous1.   

Abstract

Mitochondrion is a cellular organelle that is present in most of the cells and is responsible for producing energy for the cell. Mitochondria have their own double-stranded DNA genome which is distinct from nuclear genome. The replication, recombination and repair of mtDNA are achieved by DNA polymerase-gamma which is encoded by POLG gene. Mutation in the mtDNA or POLG gene might lead to mitochondrial dysfunction and disease. Several mutations and polymorphisms in these regions have been associated to mitochondrial disorders. Nuceloside and nucelotide reverse transcriptase inhibitors (NRTIs) that form the basis of AIDS therapy have significantly increased the survival rate of HIV-infected individuals predisposing them to other side effects. One of the most common side effects of NRTI usage is mitochondrial toxicity leading to several mitochondrial disorders. Mutations in mtDNA have also been associated to the use of specific NRTIs leading to specific mitochondrial disorders. This review briefly summarizes the advances in mtDNA mutations and NRTI-caused mitochondrial toxicity and mutations.

Entities:  

Keywords:  Mitochondrial toxicity; NRTI; mtDNA; mutation

Mesh:

Substances:

Year:  2014        PMID: 25211089     DOI: 10.3109/19401736.2014.958728

Source DB:  PubMed          Journal:  Mitochondrial DNA A DNA Mapp Seq Anal        ISSN: 2470-1394            Impact factor:   1.514


  7 in total

1.  Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.

Authors:  Lin Song; Sha Ding; Zhen Ge; Xiaolong Zhu; Cong Qiu; Yuewen Wang; Enyin Lai; Weijun Yang; Yi Sun; Samson A Chow; Luyang Yu
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 2.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

Review 3.  Investigational reverse transcriptase inhibitors for the treatment of HIV.

Authors:  Theodore J Cory; Narasimha M Midde; Pss Rao; Santosh Kumar
Journal:  Expert Opin Investig Drugs       Date:  2015-06-19       Impact factor: 6.206

4.  Nucleoside reverse transcriptase inhibitor-induced rat oocyte dysfunction and low fertility mediated by autophagy.

Authors:  Li Tang; Shengfu Yang; Huawei Wang; Hai Gu; Xueshan Xia; Yue Feng; Zexing Yang; Shuhua Zhao; Cunmei Su; Zhenfang Su; Kunhua Wang
Journal:  Oncotarget       Date:  2017-12-13

5.  The Δ133p53 Isoform Reduces Wtp53-induced Stimulation of DNA Pol γ Activity in the Presence and Absence of D4T.

Authors:  Kai Liu; Yunjin Zang; Xianghua Guo; Feili Wei; Jiming Yin; Lijun Pang; Dexi Chen
Journal:  Aging Dis       Date:  2017-04-01       Impact factor: 6.745

Review 6.  The Novel Roles of Connexin Channels and Tunneling Nanotubes in Cancer Pathogenesis.

Authors:  Silvana Valdebenito; Emil Lou; John Baldoni; George Okafo; Eliseo Eugenin
Journal:  Int J Mol Sci       Date:  2018-04-24       Impact factor: 5.923

7.  Single nucleotide polymorphisms in LCAT may contribute to dyslipidaemia in HIV-infected individuals on HAART in a Ghanaian population.

Authors:  Simon Bannison Bani; Kwabena Owusu Danquah; Christian Obirikorang; William K B A Owiredu; Lawrence Quaye; Edmund Muonir Der; Emmanuel Acheampong; Yussif Adams; Peter Paul M Dapare; Moses Banyeh; Enoch Odame Anto; Samuel Asamoah Sakyi
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.